2006
DOI: 10.1158/1535-7163.mct-06-0286
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The successful use of transcriptional targeting for cancer therapy depends on the activity of a given promoter inside the malignant cell. Because solid human tumors evolve as a ''cross-talk'' between the different cell types within the tumor, we hypothesized that targeting the entire tumor mass might have better therapeutic effect. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein overexpressed in different human cancers malignant melanomas both in the malignant cells compartment … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2007
2007
2020
2020

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 17 publications
(13 citation statements)
references
References 29 publications
0
13
0
Order By: Relevance
“…The final outcome of SPARC function will undoubtedly be highly context dependent [Framson and Sage, ]. The development of SPARC‐peptide models, conditional/gene inactivation models [Ledda et al, ; Briggs et al, ; Smit et al, ] or the transcriptional targeting using SPARC promoter [Sato et al, ; Suzuki et al, ; Kelly et al, ; Lopez et al, ; Yang et al, ; Cheetham et al, ] could be a valid strategy to understand how SPARC influences tumor invasion and metastasis and may lead to the development of anti‐angiogenic, proliferation or counter‐adhesive therapeutic treatment against metastatic bone tumors.…”
Section: Discussionmentioning
confidence: 99%
“…The final outcome of SPARC function will undoubtedly be highly context dependent [Framson and Sage, ]. The development of SPARC‐peptide models, conditional/gene inactivation models [Ledda et al, ; Briggs et al, ; Smit et al, ] or the transcriptional targeting using SPARC promoter [Sato et al, ; Suzuki et al, ; Kelly et al, ; Lopez et al, ; Yang et al, ; Cheetham et al, ] could be a valid strategy to understand how SPARC influences tumor invasion and metastasis and may lead to the development of anti‐angiogenic, proliferation or counter‐adhesive therapeutic treatment against metastatic bone tumors.…”
Section: Discussionmentioning
confidence: 99%
“…In the setting of an established tumor, researchers can utilize geographic restriction of SPARC expression to target novel imaging and therapeutic interventions. Drug delivery to the stromal component of a tumor might facilitate localregional treatment of a tumor, as demonstrated by Lopez et al [2006] with the expression of thymidine kinase under the control of the SPARC promoter. Similarly, Kelly et al [2006] have developed an in vivo tumor imaging system based on fluorochrome-labeled phage technology that detects SPARC protein within the tumor microenvironment.…”
Section: Discussionmentioning
confidence: 99%
“…These results support a central role for Osteonectin regulation in the axis of gene expression changes that occur during melanoma progression. Future work on the signaling pathway surrounding Osteonectin, involving both FAK and ILK,36 will hopefully provide further insight into the regulatory processes associated with invasive tumours and perhaps lead to a related anti cancer drug therapy targeting these regulatory processes 58, 59…”
Section: Discussionmentioning
confidence: 99%